The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

13

Transcript of The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Page 1: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 2: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 3: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 4: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 5: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 6: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 7: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 8: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 9: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 10: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 11: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 12: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer
Page 13: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity

Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity

Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

Prevalence of the fibrinogen β-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies

Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl-D-Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis

Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl-D-Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis

Characterization of heme as activator of Toll-like receptor 4

Characterization of heme as activator of Toll-like receptor 4

Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

Very Low Density Lipoprotein-Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells

Very Low Density Lipoprotein-Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells

eIF2B activator prevents neurological defects caused by a ...

eIF2B activator prevents neurological defects caused by a ...

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty

Soluble Urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

Soluble Urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage: The Intraventricular Hemorrhage Thrombolysis Trial

Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage: The Intraventricular Hemorrhage Thrombolysis Trial

Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis

and context-specific changes in tissue-type plasminogen ...

and context-specific changes in tissue-type plasminogen ...

Plasminogen activators promote excitotoxicity-induced retinal damage

Plasminogen activators promote excitotoxicity-induced retinal damage

Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor1 1

Tumor Development Is Retarded in Mice Lacking the Gene for Urokinase-Type Plasminogen Activator or Its Inhibitor, Plasminogen Activator Inhibitor1 1

Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy

Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy

Requirement of TRAP/Mediator for Both Activator-Independent and Activator-Dependent Transcription in Conjunction with TFIID-Associated TAFIIs

Requirement of TRAP/Mediator for Both Activator-Independent and Activator-Dependent Transcription in Conjunction with TFIID-Associated TAFIIs